Comparing Apixaban Vs Rivaroxaban For Atrial Fibrillation Patients: An Effectiveness And Safety Analysis

Abstract

Apixaban and Rivaroxaban, two direct oral anticoagulants, are being compared for their efficacy and safety in the treatment of atrial fibrillation as part of the study's aims.

The most common arrhythmia, atrial fibrillation (AF), is expensive for the healthcare system because of its high death and morbidity rates, which are mostly caused by thromboembolic consequences. In order to treat patients with atrial fibrillation, we thoroughly analyze the safety and effectiveness of two novel anticoagulant drugs in this study: rivaroxaban and apixaban.

In conclusion, In our study we try to investigate and compare the relatively new two anticoagulants Apixaban and Rivaroxaban regarding their effectiveness and safety in managing atrial fibrillation.